News

TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of ocular surface related diseases, today announced the successful closure of a $3M Series B round designed to accelerate its development programs for rare corneal diseases at both pre-clinical and clinical stages. “This round of financing is significant for several reasons, …

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced the appointment of Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of its Board of Directors, effective immediately. Edward A. “Buzz” Heidt Jr., who has served …

Virginia Commonwealth University’s School of Education has secured a four-year, $1.7 million federal grant to pursue a research project aimed at enhancing science learning opportunities for historically marginalized middle school students. The project integrates scientific discourse with students’ everyday experiences, while leveraging technology for a more inclusive approach to science education. Called “Hybrid2: Creating Equitable Spaces for …